logo
Plus   Neg
Share
Email

Brown-Forman Q4 Profit Down - Quick Facts

Brown-Forman Corp. (BFA,BFB) reported that its net income for the fourth quarter ended April 30, 2018 decreased 23 percent to $110 million from $144 million in the previous year.

In the quarter, reported operating income declined 32% to $145 million (-4% on an underlying basis) and earnings per share of $0.23 declined 24%. Fourth quarter reported operating income and earnings per share were both negatively impacted by the previously announced creation of a $70 million charitable foundation, as well as the phasing of operating expenses.

Quarterly net sales increased 6% to $733 million compared to the same prior-year period. Net sales were up 5% on an underlying basis.

For fiscal year 2019, the company expects earnings per share of $1.75 to $1.85 incorporates a tax rate of 21% as well as approximately five cents of negative impact from higher interest expense, foreign exchange and anticipated changes in net inventories.

The company projects underlying net sales growth of 6% to 7%, underlying operating income growth of 7% to 9% for fiscal year 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
RELATED NEWS
Follow RTT
>